Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

Published:2024-08 Issue:8 Volume:12 Page:545-557
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Apperloo Ellen M,Neuen Brendon L,Fletcher Robert A,Jongs Niels,Anker Stefan D,Bhatt Deepak L,Butler Javed,Cherney David Z I,Herrington William G,Inzucchi Silvio E,Jardine Meg J,Liu Chih-Chin,Mahaffey Kenneth W,McGuire Darren K,McMurray John J V,Neal Bruce,Packer Milton,Perkovic Vlado,Sabatine Marc S,Solomon Scott D,Staplin Natalie,Szarek Michael,Vaduganathan Muthiah,Wanner Christoph,Wheeler David C,Wiviott Stephen D,Zannad Faiez,Heerspink Hiddo J L

Funder

National Health and Medical Research Council

Ramaciotti Foundations

Publisher

Elsevier BV

Reference36 articles.

1. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials;Lancet,2022

2. Cardiovascular disease and risk management: standards of care in diabetes-2024;ElSayed;Diabetes Care,2024

3. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes;Marx;Eur Heart J,2023

4. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns;Levin;Kidney Int,2024

5. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials;Sattar;Lancet Diabetes Endocrinol,2021

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In T2DM with CKD, semaglutide reduced major kidney disease events at 3 y;Annals of Internal Medicine;2024-09-03

2. Targeting HFpEF: Unlocking the Potential of Glucagon Receptor Blockade;Circulation Research;2024-08-16

3. Diabetic kidney disease—Recent updates;Journal of Diabetes;2024-08

4. SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?;The Lancet Diabetes & Endocrinology;2024-08

5. Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes;Journal of the American College of Cardiology;2024-08